Protein Tomography ? to Improve Success in Drug Development

FEI Company and Sweden-based Sidec Technologies AB are collaborating on the commercialization of Protein Tomography? solutions and services based on Sidec's proprietary software and intellectual property, and FEI's transmission electron microscopes (TEMs).

Protein Tomography is a new technology developed to address critical issues around drug target validation and translational medicine in the pharmaceutical industry, improving target validation processes and shortening development time for new pharmaceuticals.

FEI has led the development of cryo electron microscopy for the imaging of biological structures in close collaboration with many top level academic groups in Europe and the US. Sidec is pioneering the field of protein imaging using cryo electron tomography and has several research collaborations with global pharmaceutical companies.

Protein Tomography consists of advanced electron microscopy instrumentation, proprietary data acquisition and reconstruction software as well as scientific expertise to enable the imaging and analysis of individual protein molecules in cells and tissues. FEI and Sidec offer this as a service through Sidec, as an on-premises service, or through a software and other intellectual property license arrangement combined with a TEM system sale.